Jump to Header Jump to Main Content Jump to Footer

TQJ230 on major cardiovascular events in patients with established cardiovascular disease

Ailin Barseghian Elfarra


A Study On:

  • Heart - Cardiovascular/ Circulatory

Status:

  • Open

Eligibility

Cardiovascular Disease and Lipoprotein(a)
18 Years to 80 Years (Adult, Older Adult)

Interested in joining this trial?

Official Title

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease


Eligibility

You can join if...

Key Inclusion Criteria

  1. Lp(a) greater than or equal to 70 mg/dL at the screening visit, measured at the Central laboratory
  2. Myocardial infarction: greater than or equal to 3 months from screening and randomization to less than or equal to 10 years prior to the screening visit
  3. Ischemic stroke: greater than or equal to 3 months from screening and randomization to less than or equal to 10 years prior to the screening visit
  4. Clinically significant symptomatic peripheral artery disease

Key Exclusion Criteria

  1. Uncontrolled hypertension
  2. Heart failure New York Heart Association (NYHA) class IV
  3. History of malignancy of any organ system
  4. History of hemorrhagic stroke or other major bleeding
  5. Platelet count less than or equal to LLN
  6. Active liver disease or hepatic dysfunction
  7. Significant kidney disease
  8. Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply at the end.

Get in touch with our study team